The estimated Net Worth of Ira Duarte is at least $203 ezer dollars as of 19 July 2024. Ira Duarte owns over 3,875 units of Cortexyme Inc stock worth over $203,048 and over the last 14 years Ira sold CRTX stock worth over $0.
Ira has made over 4 trades of the Cortexyme Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Ira exercised 3,875 units of CRTX stock worth $7,556 on 19 July 2024.
The largest trade Ira's ever made was buying 85,000 units of Cortexyme Inc stock on 16 November 2023 worth over $75,650. On average, Ira trades about 11,694 units every 27 days since 2011. As of 19 July 2024 Ira still owns at least 104,127 units of Cortexyme Inc stock.
You can see the complete history of Ira Duarte stock trades at the bottom of the page.
Ira's mailing address filed with the SEC is 4242 CAMPUS POINT COURT, SUITE 200, , SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi és Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: